A commercialization plan explains how the technology will move from funded R&D into use by customers, industry, government, patients, or other adopters. For SBIR and deeptech grants, it should cover market need, users, competitors, intellectual property, adoption barriers, milestones, follow-on funding, and the route from technical success to practical use.
Commercialization plans are often written too late. The technical proposal gets most of the founder's attention, and the commercialization section becomes a short market paragraph plus a revenue claim. That is risky. For SBIR, STTR, and many deeptech programmes, reviewers need to believe that technical success will lead somewhere real.
A strong commercialization plan does not pretend that a grant-funded prototype will instantly become a large business. It explains the next credible steps. Who has the problem? How do they buy or adopt solutions? What regulatory, manufacturing, reimbursement, procurement, or integration barriers remain? What evidence will the grant create? What funding, partnership, or customer milestone comes next?
Use this guide with SBIR/STTR for deeptech startups, NSF Seed Fund for startups, and the deeptech funding roadmap. For proposal structure, see grant proposal sections.
Quick answer: what a commercialization plan includes
A commercialization plan should show that the applicant understands the market and the path to adoption. It should include the customer or user, the problem being solved, the competitive landscape, the value proposition, intellectual property position, adoption barriers, development milestones, revenue or deployment path, team capability, and follow-on funding strategy.
| Section | Question it answers | Evidence to include |
|---|---|---|
| Customer and use case | Who needs this and why? | Customer interviews, pilots, letters, procurement pain, clinical or industrial workflow. |
| Market opportunity | Is the opportunity meaningful and focused? | Segment size, beachhead market, buyer type, adoption setting. |
| Competition | Why is this better than alternatives? | Current solutions, switching cost, performance gap, differentiation. |
| IP and defensibility | Can the company capture value? | Patents, know-how, data, regulatory moat, manufacturing process, trade secrets. |
| Barriers | What still blocks adoption? | Regulatory, reimbursement, manufacturing, certification, procurement, integration, sales-cycle risk. |
| Milestones and funding | What happens after the grant? | Post-award development plan, Phase II path, pilots, investors, strategic partners, revenue assumptions. |
The most important word is path. Reviewers do not need a fantasy forecast. They need a plausible sequence from current evidence to funded milestone to next decision. If the technology is too early for sales, say what evidence is needed before sales. If regulation is required, say what interaction or study comes next. If manufacturing is unresolved, say what scale-up assumption the grant will test.
Commercialization plan vs business plan
A commercialization plan is not the same as a full business plan. A business plan may cover company strategy, hiring, sales operations, finance, and long-term growth. A commercialization plan inside a grant application should focus on how the funded technology can move toward use. It is narrower, more evidence-driven, and more connected to the technical work.
This matters because founders sometimes paste investor-deck language into grants. Investor language often emphasizes market size, speed, and upside. Grant reviewers often need a different kind of confidence: technical feasibility, development sequence, adoption barriers, and whether public R&D funds will unlock the next stage. The commercialization plan should translate company ambition into funder-relevant evidence. If a panel deck is required, the grant pitch deck example shows how to avoid turning it into an investor deck.
- A business plan sells the company. It explains how the venture can grow and capture value.
- A commercialization plan de-risks adoption. It explains how the technology can move from R&D result to practical use.
- A grant commercialization plan must match the funded work. If the grant funds feasibility, the plan should not pretend full market launch is already solved.
What SBIR reviewers look for
SBIR and STTR reviewers often look for more than scientific merit. They need to understand whether the company sees a real commercial path. That does not mean every early Phase I proposal needs complete revenue traction. It means the applicant should understand the target market, barriers, customers, competition, intellectual property, and follow-on milestones.
In Phase II and Fast-Track contexts, commercialization scrutiny usually increases. Reviewers may ask whether the company understands market segments, customer preferences, regulatory approval, reimbursement, competition, and product-development milestones. If the plan treats commercialization as a future problem, it can weaken an otherwise strong technical application.
| Reviewer concern | Weak answer | Stronger answer |
|---|---|---|
| Market understanding | The market is large and growing. | The first target segment is hospital outpatient labs that need faster resistance testing because current workflows delay treatment decisions. |
| Customer evidence | Customers are interested. | Three pilot sites identified workflow bottlenecks and agreed to evaluate prototype usability after analytical validation. |
| Regulatory barrier | We will pursue approvals. | The next milestone is a pre-submission interaction to confirm validation study design after prototype performance is established. |
| Competition | No direct competitors exist. | Current alternatives solve part of the workflow but fail on turnaround time and sample preparation burden. |
| Follow-on funding | We will raise investment. | Successful completion supports a Phase II application and a seed round tied to pilot and regulatory milestones. |
Market, customers, and adoption pathway
A commercialization plan should start with a focused market, not the largest possible market. If the first customer segment is too broad, the adoption pathway becomes vague. Deeptech companies often sell into complex environments: hospitals, manufacturers, utilities, defense organizations, agriculture, aerospace, pharma, or regulated infrastructure. Each has a different buying process.
Describe the user, buyer, and decision-maker separately when they differ. In medtech, the user may be a clinician, the buyer may be a hospital system, and the payer may be separate. In industrial robotics, the user may be an operations team while procurement, safety, and engineering all influence adoption. In defense, the first adoption path may involve pilots, primes, or government procurement rather than standard SaaS sales.
The plan should also distinguish interest from adoption evidence. A friendly conversation shows a lead. A documented workflow problem shows need. A pilot site shows access. A signed letter that describes evaluation criteria shows stronger pull. Paid use, procurement planning, or strategic partnership discussion is stronger again. Do not collapse these stages into one vague claim that customers want it.
- Name the first beachhead market. Reviewers trust a narrow first segment more than a vague total addressable market.
- Explain the adoption workflow. Who tests it, who approves it, who pays for it, and what must change operationally?
- Use customer evidence carefully. Letters, interviews, pilots, and advisory input are useful, but do not overstate purchase commitments.
- Connect market evidence to the grant milestone. If the grant creates a prototype, say what customer question that prototype will answer.
Barriers: regulatory, reimbursement, procurement, manufacturing, and IP
A weak commercialization plan describes only opportunity. A strong one describes barriers and the strategy for addressing them. This is not negative. It shows maturity. Deeptech adoption is usually blocked by more than product awareness. The barrier may be regulatory approval, reimbursement, certification, safety validation, manufacturing yield, integration burden, procurement cycles, data security, or capital expenditure.
| Barrier | What to explain | Evidence to mention |
|---|---|---|
| Regulatory | Which pathway or interaction is likely next. | Advisor input, predicate analysis, study plan, standards. |
| Reimbursement | How payment or economic value may work. | Coding assumptions, health economics, stakeholder interviews. |
| Manufacturing | How the product can be made reliably. | Supplier input, process steps, yield assumptions, quality constraints. |
| Procurement | How the buyer evaluates and purchases. | Pilot requirements, procurement route, budget owner, buying cycle. |
| IP | How the company can protect or defend value. | Patent filings, trade secrets, data advantage, licensing position. |
| Integration | How the solution fits the user's workflow. | API, hardware interface, training, installation, support needs. |
Do not claim barriers are solved unless they are solved. The better move is to show which barrier the grant addresses and which barriers remain for the next stage. This makes the plan more credible and helps reviewers understand why non-dilutive funding is appropriate now.
Milestones and follow-on funding
A commercialization plan should make the post-grant path visible. The funded project may not produce revenue immediately, but it should produce evidence that enables the next step. That next step could be Phase II, a pilot, a regulatory meeting, a seed round, a strategic partnership, a manufacturing trial, or a first paid deployment.
| Grant output | Commercialization implication | Next-step evidence |
|---|---|---|
| Feasibility prototype | Can support Phase II or pilot discussions. | Performance data, user feedback, risk register. |
| Validated assay or benchmark | Can support clinical or regulatory planning. | Analytical results, sample set description, advisor feedback. |
| Field demonstration | Can support customer adoption discussions. | Deployment metrics, operator feedback, integration issues. |
| Manufacturing process test | Can support scale-up funding. | Yield, cost model, supplier quotes, quality constraints. |
| Customer discovery package | Can support investor and partner conversations. | Segment analysis, buying criteria, letters, pilot pipeline. |
For more on sequencing grants with company milestones, see the deeptech funding roadmap and non-dilutive funding vs VC.
Commercialization plan template
Use the template below as a drafting structure. Adjust it to the funder instructions. Some agencies prescribe exact headings, page limits, or review criteria. If the funder gives a format, follow it first. Use this as a logic check.
- Product or technology. What is being commercialized, what stage is it at, and what will the grant change?
- Customer and problem. Who has the problem, how painful is it, and how is it solved today?
- Market segment. What is the first focused segment and why is it the right entry point?
- Competition and differentiation. What alternatives exist and why is this approach meaningfully better?
- IP and defensibility. What protects the company or creates a durable advantage?
- Barriers and risks. What regulatory, manufacturing, reimbursement, procurement, integration, or adoption risks remain?
- Milestones. What will happen during the grant and what next-stage evidence will exist?
- Funding and partnerships. What capital, partners, pilots, or customers are needed after the grant?
Before you submit, check whether the commercialization plan connects five things: a specific customer segment, the adoption barrier, the grant-funded evidence, the next milestone, and the funding or partnership step after the grant.
Common mistakes
Commercialization sections fail when they sound like investor slides detached from the grant work. Reviewers may believe the market exists and still doubt that this project moves the company toward it. The section should be ambitious, but it must remain anchored in evidence.
- Leading with total market size. Start with the first customer segment and adoption problem, then scale out.
- Ignoring barriers. If regulation, reimbursement, manufacturing, procurement, or integration matters, name it and show the plan.
- Overstating customer commitment. A conversation is not a purchase order. A pilot interest letter is not revenue.
- Separating commercialization from technical milestones. The plan should show how the funded work produces evidence for the next commercial step.
- Using generic business language. Reviewers need specific customers, constraints, milestones, and evidence, not startup vocabulary.
The fix is to write the commercialization plan as a sequence of decisions. What must be true before the customer can adopt? What must be true before investors or strategic partners engage? What must be true before regulatory, manufacturing, or procurement risk drops? Then show how the grant-funded project produces evidence for those decisions.